Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Average Rating of “Moderate Buy” by Analysts

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have earned an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $19.6667.

A number of analysts recently issued reports on the stock. UBS Group upgraded shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 price target for the company in a research note on Wednesday, July 8th. Wall Street Zen downgraded shares of Tvardi Therapeutics to a “strong sell” rating in a research note on Saturday, July 18th. BTIG Research reissued a “buy” rating and issued a $15.00 target price on shares of Tvardi Therapeutics in a research report on Tuesday, July 7th. HC Wainwright assumed coverage on shares of Tvardi Therapeutics in a research note on Monday, June 8th. They issued a “buy” rating and a $9.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Wednesday, July 8th.

Tvardi Therapeutics Stock Down 12.3%

Shares of NASDAQ TVRD opened at $2.14 on Thursday. Tvardi Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $43.65. The business has a 50 day moving average price of $2.82 and a two-hundred day moving average price of $3.41. The firm has a market cap of $20.07 million, a PE ratio of -0.69 and a beta of 0.39.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its earnings results on Friday, May 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.08). On average, analysts anticipate that Tvardi Therapeutics will post -2.32 earnings per share for the current year.

Institutional Trading of Tvardi Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. American Financial Group Inc. acquired a new position in shares of Tvardi Therapeutics in the 4th quarter worth approximately $962,000. Vestal Point Capital LP acquired a new stake in shares of Tvardi Therapeutics during the 3rd quarter valued at approximately $6,508,000. Geode Capital Management LLC bought a new position in Tvardi Therapeutics during the second quarter worth $2,617,000. Invesco Ltd. acquired a new position in Tvardi Therapeutics in the third quarter worth $3,219,000. Finally, Renaissance Technologies LLC boosted its holdings in Tvardi Therapeutics by 246.3% in the fourth quarter. Renaissance Technologies LLC now owns 104,500 shares of the company’s stock worth $449,000 after purchasing an additional 74,325 shares during the period. Institutional investors and hedge funds own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.